Amgen Inc. is confronting a significant legal challenge as the U.S. Court of Appeals invalidated its patents on the cholesterol-lowering drug Repatha, threatening nearly $1.3 billion in sales. Sanofi has labeled Amgen's attempt to revive these patents as a blatant strategy to eliminate competition from rivals like Regeneron, which earned $130 million from its competing drug, Praluent. The Biden administration has sided with Sanofi, complicating Amgen's appeal process, with a decision anticipated by the end of June.
“Amgen Inc · is set to hear a bid · patents on its cholesterol-lowering drug Repatha · true”
“Sanofi SA · called · Amgen's attempt to revive patents · blatant attempt”
“Repatha · can reduce risk of · heart attack and stroke · true”
“Amgen · sold · Repatha worldwide · nearly $1.3 billion”
“Regeneron · sold · Praluent in the United States · $130 million”
“Sanofi · sold · Praluent in the rest of the world · more than $400 million”
“U.S. Court of Appeals for the Federal Circuit · invalidated · Amgen's patents · true”
“Sanofi · urged the justices to affirm · the Federal Circuit's ruling · true”
“President Joe Biden's administration · is supporting · Sanofi in the dispute · true”
“Amgen · garners · sales · $1.5 billion”
“Amgen · sued · Sanofi and Regeneron · 2014”
“Regeneron · made · revenue · $130 million”
